Iambic Therapeutics (IAM) closed at $10.17 on November 6, 2026, down 12.6% from the previous close, on volume of 667,413 shares (30-day average 841,921).
Data as of November 6, 2026.
No headlines found.
Iambic Therapeutics Inc is a technology and clinical-stage life sciences company developing novel medicines using its proprietary molecular superintelligence platform.
Iambic Therapeutics trades on the NASDAQ stock market under the symbol IAM.
As of November 6, 2026, IAM stock price declined to $10.17 with 667,413 million shares trading.
IAM has a market cap of $482.07 million. This is considered a Small Cap stock.
The top ETF exchange traded funds that IAM belongs to (by Net Assets): ARKG.
IAM support price is $10.38 and resistance is $12.90 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that IAM shares will trade within this expected range on the day.
